380 related articles for article (PubMed ID: 9737485)
1. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography.
Mody FV; Singh BN; Mohiuddin IH; Coyle KB; Buxton DB; Hansen HW; Sumida R; Schelbert HR
Am J Cardiol; 1998 Sep; 82(5A):42K-49K. PubMed ID: 9737485
[TBL] [Abstract][Full Text] [Related]
2. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
Kantor PF; Lucien A; Kozak R; Lopaschuk GD
Circ Res; 2000 Mar; 86(5):580-8. PubMed ID: 10720420
[TBL] [Abstract][Full Text] [Related]
3. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy.
Belardinelli R
Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V35-9. PubMed ID: 11206102
[TBL] [Abstract][Full Text] [Related]
4. The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway.
Liu Z; Chen JM; Huang H; Kuznicki M; Zheng S; Sun W; Quan N; Wang L; Yang H; Guo HM; Li J; Zhuang J; Zhu P
Metabolism; 2016 Mar; 65(3):122-30. PubMed ID: 26892523
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effect of trimetazidine on utilization of myocardial glycogen during coronary ligation in dogs.
Sakai K; Fukushi Y; Abiko Y
Pharmacology; 1986; 32(2):72-9. PubMed ID: 3952133
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase.
Lopaschuk GD; Barr R; Thomas PD; Dyck JR
Circ Res; 2003 Aug; 93(3):e33-7. PubMed ID: 12869392
[TBL] [Abstract][Full Text] [Related]
7. Trimetazidine normalizes postischemic function of hypertrophied rat hearts.
Saeedi R; Grist M; Wambolt RB; Bescond-Jacquet A; Lucien A; Allard MF
J Pharmacol Exp Ther; 2005 Jul; 314(1):446-54. PubMed ID: 15840766
[TBL] [Abstract][Full Text] [Related]
8. Trimetazidine reduces endogenous free fatty acid oxidation and improves myocardial efficiency in obese humans.
Bucci M; Borra R; Någren K; Pärkkä JP; Del Ry S; Maggio R; Tuunanen H; Viljanen T; Cabiati M; Rigazio S; Taittonen M; Pagotto U; Parkkola R; Opie LH; Nuutila P; Knuuti J; Iozzo P
Cardiovasc Ther; 2012 Dec; 30(6):333-41. PubMed ID: 21884010
[TBL] [Abstract][Full Text] [Related]
9. Effects of trimetazidine on ischemic contracture in isolated perfused rat hearts.
Boucher FR; Hearse DJ; Opie LH
J Cardiovasc Pharmacol; 1994 Jul; 24(1):45-9. PubMed ID: 7521488
[TBL] [Abstract][Full Text] [Related]
10. Early recovery of regional performance in salvaged ischemic myocardium following coronary artery occlusion in the dog.
Darsee JR; Kloner RA; Braunwald E
J Clin Invest; 1981 Jul; 68(1):225-39. PubMed ID: 7019244
[TBL] [Abstract][Full Text] [Related]
11. Demand-induced ischemia in volume expanded isolated rat heart; the effect of dichloroacetate and trimetazidine.
Skierczynska A; Beresewicz A
J Physiol Pharmacol; 2010 Apr; 61(2):153-62. PubMed ID: 20436215
[TBL] [Abstract][Full Text] [Related]
12. Glucose delivery is a major determinant of glucose utilisation in the ischemic myocardium with a residual coronary flow.
King LM; Opie LH
Cardiovasc Res; 1998 Aug; 39(2):381-92. PubMed ID: 9798523
[TBL] [Abstract][Full Text] [Related]
13. Enhanced myocardial 18F-2-fluoro-2-deoxyglucose uptake after orthotopic heart transplantation assessed by positron emission tomography.
Rechavia E; de Silva R; Kushwaha SS; Rhodes CG; Araujo LI; Jones T; Maseri A; Yacoub MH
J Am Coll Cardiol; 1997 Aug; 30(2):533-8. PubMed ID: 9247529
[TBL] [Abstract][Full Text] [Related]
14. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study.
El-Kady T; El-Sabban K; Gabaly M; Sabry A; Abdel-Hady S
Am J Cardiovasc Drugs; 2005; 5(4):271-8. PubMed ID: 15984909
[TBL] [Abstract][Full Text] [Related]
15. Ionic and metabolic imbalance as potential factors of ischemia reperfusion injury.
El Banani H; Bernard M; Cozzone P; James F; Feuvray D
Am J Cardiol; 1998 Sep; 82(5A):25K-29K. PubMed ID: 9737483
[TBL] [Abstract][Full Text] [Related]
16. Myocardial blood flow, metabolism, and inotropic reserve in dogs with dysfunctional noninfarcted collateral-dependent myocardium.
Gerber BL; Laycock S; Melin JA; Borgers M; Flameng W; Vanoverschelde JL
J Nucl Med; 2002 Apr; 43(4):556-65. PubMed ID: 11937602
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of nicorandil, nitroglycerin, nicotinic acid, and SG-86 on the metabolic status and functional recovery of the ischemic-reperfused myocardium.
Gross GJ; Pieper GM; Warltier DC
J Cardiovasc Pharmacol; 1987; 10 Suppl 8():S76-84. PubMed ID: 2447429
[TBL] [Abstract][Full Text] [Related]
18. Quantitative assessment of prolonged metabolic abnormalities in reperfused canine myocardium.
Buxton DB; Mody FV; Krivokapich J; Phelps ME; Schelbert HR
Circulation; 1992 May; 85(5):1842-56. PubMed ID: 1572040
[TBL] [Abstract][Full Text] [Related]
19. Substrate use in ischemic and reperfused canine myocardium: quantitative considerations.
Myears DW; Sobel BE; Bergmann SR
Am J Physiol; 1987 Jul; 253(1 Pt 2):H107-14. PubMed ID: 3605356
[TBL] [Abstract][Full Text] [Related]
20. [Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism].
Lopaschuk GD
Presse Med; 1998 Dec; 27(39):2100-4. PubMed ID: 9893703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
